ArticleScientific reports2026
Hepatic transcriptomic and functional responses to ketogenic diet intervention in MASLD-Induced male albino rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the potential therapeutic effects of the ketogenic diet (KD) on metabolic dysfunction-associated steatotic liver disease (MASLD). Forty male albino rats were randomly assigned to four groups: a control group, a MASLD group fed a high-fructose high-fat diet (HFFD) for eight weeks, a KD group provided a diet consisting of 65% fat, 25% protein, and 5% carbohydrates for 16 weeks, and a MASLD + KD group subjected to HFFD followed by KD. The MASLD group exhibited significant increases in serum leptin (1.94 ± 0.54 ng/mL vs. 1.24 ± 0.23 ng/mL in controls), urea (42.3 ± 4.5 mg/dL vs. 26.92 ± 6.57 mg/dL in controls), creatinine (0.97 ± 0.8 mg/dL vs. 0.67 ± 0.1 mg/dL in controls), triglycerides (98.6 ± 18.5 mg/dL vs. 78.6 ± 9.2 mg/dL in controls), and LDL cholesterol (89.9 ± 12 mg/dL vs. 40.8 ± 4.9 mg/dL in controls), while adiponectin (1.98 ± 0.21 µg/mL vs. 4.58 ± 0.69 µg/mL in controls) and HDL (21.4 ± 3.5 mg/dL vs. 39.8 ± 5.2 mg/dL in controls) were markedly reduced. Gene expression analysis revealed that Growth Arrest Specific 5 (GAS5), Neurogenic Locus Notch Homolog Protein 1 (Notch-1), H19, peroxisome proliferator-activated receptor gamma (PPARγ), stearoyl-CoA desaturase-1 (SCD1), acetyl-CoA carboxylase-1 (ACC1), fatty acid synthase (FASN), Neat-1, miR-139-5p, c-Jun, sterol regulatory element-binding transcription factor-1c (SREBF1c), Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT-1), aryl hydrocarbon receptor nuclear translocator (ARNT-1), and CD36 were significantly (p < 0.0001) upregulated in the MASLD group compared with the other groups. In contrast, the KD group demonstrated notable upregulation of microRNAs (miR-29a-3p, miR-130a, miR-139-5p, miR-206) and peroxisome proliferator-activated receptor alpha (PPARα) compared with the MASLD and MASLD + KD groups. Overall, the KD group exhibited the most pronounced improvements in metabolic, renal, and molecular parameters. These findings suggest that KD intervention may confer beneficial effects on metabolic and genetic pathways in MASLD, although causality cannot be definitively established in this experimental model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.